Haemonetics Plasma Franchise Returns to Growth Amid Debt Concerns

Zacks Investment Research··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Haemonetics Corporation's Plasma franchise returned to growth in the fourth quarter of fiscal 2026, with revenues of $130 million, up 3% on a reported basis and 13% on an organic basis excluding CSL. The company's NexSys PCS plasma collection system continues to thrive, and Haemonetics signed new long-term agreements with BioLife and Grifols in fiscal 2025. However, a debt-burdened balance sheet remains a concern, with long-term debt of $1.22 billion and a debt-to-capital ratio of 50.2% at the end of the fiscal fourth quarter. The Zacks Consensus Estimate for fiscal 2026 earnings has moved south 1 cent to $5.22 per share in the past 30 days, while the revenue estimate is pegged at $1.40 billion, indicating a 4.9% decrease from the year-ago reported number. Haemonetics shares have lost 2.4% over the past year, compared with the industry's decline of 29.5%.

Impact on assets 6

Biotech & Genomic Medicine▲ · 3 stocks
Haemonetics Corporation
HAE
▲ PositiveDemandCapitalrelevance

Plasma franchise returned to growth with revenues up 13% organically, and new long-term agreements with BioLife and Grifols.

Health Care▲ · 2 stocks
Robotics & Physical AI▲ · 1 stocks

Off-coverage companies 1

CSL LimitedPrivate± Mixed
relevance

© 2026 MarketIVNews